Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:acquiredBy |
purchased Cadence Pharmaceuticals in 2014
purchased Questcor Pharmaceuticals in 2014 |
| gptkbp:CEO |
gptkb:Siggi_Olafsson
|
| gptkbp:countryOfOperation |
gptkb:Ireland
|
| gptkbp:foundedYear |
2013
|
| gptkbp:hasCompany |
gptkb:Mallinckrodt_plc
|
| gptkbp:headquartersLocation |
gptkb:Staines-upon-Thames,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
NYSE: MNK
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:ISIN |
IE00BLL8HL04
|
| gptkbp:listedOn |
gptkb:New_York_Stock_Exchange
|
| gptkbp:marketCap |
varies (subject to market conditions)
|
| gptkbp:notableEvent |
filed for bankruptcy in 2020 and 2023
involved in opioid litigation |
| gptkbp:predecessor |
Covidien plc
|
| gptkbp:product |
generic drugs
specialty pharmaceuticals imaging agents |
| gptkbp:stockSymbol |
gptkb:MNK
|
| gptkbp:tradedOn |
gptkb:NYSE:_MNK
|
| gptkbp:website |
https://www.mallinckrodt.com/
|
| gptkbp:bfsParent |
gptkb:Mallinckrodt
|
| gptkbp:bfsLayer |
7
|